meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC)</span>
<span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">pembrolizumab based treatment</span>
<span style="margin-left: 3em;">pembrolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
KEYNOTE-590, 0
placebo plus SoC
pembrolizumab plus SoC
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
placebo plus SoC
pembrolizumab plus SoC
placebo plus SoC
---
NA
pembrolizumab plus SoC
NA
---
pathologies: 150 - treatments: 873
result logic
×
Study list
